Summary
The advent of ctDNA has the potential to be a game changer in some cancers, but limited data is available in oesophago-gastric cancers (OGC). The prognostic value of ctDNA and the potential for false positive results due to clonal haematopoiesis of indeterminate potential (CHIP) was recently reported in operable OGC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Abbosh, C., Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 545, 446–451 (2017).
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 8, 346ra92 (2016).
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S., Moore, K. L., Joshi, S. S. et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin. Cancer Res. 25, 7098–7112 (2019).
Leal, A., van Grieken, N. C., Palsgrove, D. N., Phallen, J., Medina, J. E., Hruban, C. et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nat. Commun. 11, 1–1 (2020).
Christensen, E., Birkenkamp-Demtröder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clini. Oncol. 37, 1547–1557 (2019).
Ococks E., Frankell A. M., Soler N. M., Grehan N., Northrop A., Coles H. et al. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann. Oncol. 32, 522–532 (2021).
Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat. Med. 25, 1928–1937 (2019).
Frankell, A. M., Jammula, S., Li, X., Contino, G., Killcoyne, S., Abbas, S. et al. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic. Nat. Genet. 51, 506–516 (2019).
Wasserman, I., Lee, L. H., Ogino, S., Marco, M. R., Wu, C., Chen, X. et al. SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance. Clin. Cancer Res. 25, 1948–1956 (2019).
CRUK. Cancer Statistics (2021).
Al-Batran, S. E., Homann, N., Pauligk, C., Goetze, T. O., Meiler, J., Kasper, S. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957 (2019).
Smyth, E. C., Fassan, M., Cunningham, D., Allum, W. H., Okines, A. F., Lampis, A. et al. Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial. J. Clin. Oncol. 34, 2721 (2016).
Acknowledgements
We acknowledge the patients who kindly agreed to take part on the Ococks et al. study.
Author information
Authors and Affiliations
Contributions
B.de.P. and E.S. contributed equally on the draft conception, writing and review.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
This manuscript is based on published data, therefore ethical approval and consent is not applicable.
Data availability
The data mentioned on this manuscript is fully available online. Any further information not provided should be discussed with the corresponding authors of each cited paper.
Competing interests
Bruno de Paula declares personal consultancy fees and/or travel in the past 5 years from: Roche and Pfizer Elizabeth Smyth declares personal consultancy fees and/or travel in the past 5 years from: Aptitude Health, Astra Zeneca, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Roche, Sai-Med, Servier, Zymeworks.
Funding information
There was no funding for this manuscript.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
De Paula, B., C Smyth, E. Personalising care in oesophageal cancer care with liquid biopsy. Br J Cancer 125, 1036–1038 (2021). https://doi.org/10.1038/s41416-021-01370-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-021-01370-5